Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Wins OSI But Victory Comes At A Price

Executive Summary

Japanese drug maker Astellas' painstaking pursuit of OSI Pharmaceuticals was rewarded on May 17 with a definitive merger agreement that has the unanimous support of both companies' boards
Advertisement

Related Content

Astellas Pays $125MM Up-Front To Share Rights To AVEO's Tivozanib
Sanofi Forces Genzyme's Hand With Hostile Bid
Regulatory Updates, In Brief
Deals Of The Week: GlaxoSmithKline/Isis, MDRNA/Sequent, Takeda/AMAG ...
Looking for Oncology Payoff, Astellas Makes Hostile Bid for Tarceva Maker OSI
Looking for Oncology Payoff, Astellas Makes Hostile Bid for Tarceva Maker OSI
Tarceva Gets Thumbs Down For NSCLC Maintenance As Cmte. Seeks Better Subgroup Analyses
Astellas Bows Out Of The CVT Sweepstakes, But What’s Next?
Takeda's Global Ambition
Astellas Advances Antibody R&D Agenda With Agensys Purchase Worth Up To $537 Million

Topics

Advertisement
UsernamePublicRestriction

Register

PS052244

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel